ISSCR News


New Podcast Episode. Climbing the Scientific Mountain of Retinal Regeneration
Announcements Megan Koch Announcements Megan Koch

New Podcast Episode. Climbing the Scientific Mountain of Retinal Regeneration

Collectively, retinal degenerative disorders are a major cause of blindness worldwide. For example, one of the most common disorders is age related macular degeneration, which alone affects nearly 200 million globally. In humans, and other mammals, the loss of the retinal cells is an irreversible process. However, in some non-mammalian vertebrates like frogs and fish, retinal neurons can regenerate. This process is dependent upon Müller glia, which can re-enter the cell cycle and reprogram into neurogenic progenitors upon retinal injury or disease. Progress has been made in understanding the genetic program underlying these regenerative process, and proof-of-principle experiments in the adult mouse retina demonstrated that genetic programs in frog and fish can be coopted to induce neurogenesis in mammals. Our guests today have extended this research to genetically reprogram fetal or organoid-derived human Müller glia into retinal neurons. They will talk about this work, the background underlying it and its potential applications.

Read More
Expanding Opportunities for Students
Message from the President Kym Kilbourne Message from the President Kym Kilbourne

Expanding Opportunities for Students

For the second year now, we have created opportunities for early career scientists, primarily trainees and postdoctoral scholars, to design their dream session at the ISSCR Annual Meeting. Not only does this give early career researchers experience with developing scientific programming, but also encourages them to build new relationships with scientists from different institutions who can share their work as part of the theme of the session.  The Science Spotlight Sessions will be held on Wednesday 10 July from 4:00 to 5:30 PM at ISSCR 2024.

Read More
The ISSCR Provides Comments on FDA’s Draft Guidance for Potency Assurance for Cellular and Gene Therapy Products 
Announcements, Policy Kym Kilbourne Announcements, Policy Kym Kilbourne

The ISSCR Provides Comments on FDA’s Draft Guidance for Potency Assurance for Cellular and Gene Therapy Products 

On 5 March 2023, the ISSCR submitted comments on the Food and Drug Administration’s draft guidance for Potency Assurance for Cellular and Gene Therapy (CGT) Products. ISSCR appreciates FDA’s commitment to assuring the potency of human CGT products at all stages of the product lifecycle. This guidance from the FDA will help our members, who are at the forefront of research and innovation, in their work.

Read More
Bayer and BlueRock Therapeutics Join the City of Hamburg and Life Sciences Nord to Co-Sponsor ISSCR 2024 in Hamburg, Germany
Announcements Kym Kilbourne Announcements Kym Kilbourne

Bayer and BlueRock Therapeutics Join the City of Hamburg and Life Sciences Nord to Co-Sponsor ISSCR 2024 in Hamburg, Germany

Find your inspiration at ISSCR 2024, The Global Stem Cell Event, taking place 10-13 July 2024 in Hamburg, Germany. The international stem cell community’s most anticipated event of the year showcases impactful research and clinical applications in a field that is driving clinical advances with the potential to bring new approaches to alleviating intractable diseases and disorders.

Read More

Receive ISSCR Press Releases

Sign up be a part of ISSCR’s media list. Media Contact: Kym Kilbourne, Director of Media and Strategic Communications

Subscribe to ISSCR News.

Each month, ISSCR delivers scientific, policy, and community to your inbox .